Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequence of argon macular grid laser and intravitreal bevacizumab in branch retinal vein occlusion with macular edema
PACTR201705002168252Completed
- Sponsor
- Ophthalmology department
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab in branch retinal vein occlusion (BRVO) and macular edema (2 arms), sponsored by Ophthalmology department. Primary endpoint: Best corrected visual effect. Started Sep 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on PACTR201705002168252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201705002168252.